Novavax (NVAX) Gains from Investment Securities (2010 - 2026)

Novavax's Gains from Investment Securities history runs 17 years deep, the most recent figure standing at $578000.0 for Q1 2026.

• In Q1 2026, Gains from Investment Securities fell 73.74% year-over-year to $578000.0; the TTM figure through Mar 2026 stood at -$7.4 million (down 137.72% YoY), while the FY2025 annual figure was -$5.8 million, down 126.39% from the prior year.
• Gains from Investment Securities was $578000.0 for Q1 2026 at Novavax, up from -$9.6 million in the prior quarter.
• In the past five years, Gains from Investment Securities ranged from a high of $47.7 million in Q4 2022 to a low of -$26.7 million in Q3 2023.
• Historically, Gains from Investment Securities has averaged $6.9 million across 5 years, with a median of $2.2 million in 2025.
• Biggest YoY gain for Gains from Investment Securities was 197.53% in 2024; the steepest drop was 921.85% in 2024.
• A 5-year view of Gains from Investment Securities shows it stood at $47.7 million in 2022, then slumped by 85.5% to $6.9 million in 2023, then surged by 197.53% to $20.6 million in 2024, then tumbled by 146.44% to -$9.6 million in 2025, then soared by 106.05% to $578000.0 in 2026.
• The last three Gains from Investment Securities figures came in at $578000.0 (Q1 2026), -$9.6 million (Q4 2025), and -$1.1 million (Q3 2025), per Business Quant data.